Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kubo, M.
Right arrow Articles by Tamaki, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kubo, M.
Right arrow Articles by Tamaki, K.
Related Collections
Right arrow Systemic Sclerosis
Right arrow Myositis and Muscle Disease
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 531-534
© 2002 British Society for Rheumatology

Original Papers

Anti-U5 snRNP antibody as a possible serological marker for scleroderma–polymyositis overlap

M. Kubo, H. Ihn, M. Kuwana1, Y. Asano, T. Tamaki, K. Yamane and K. Tamaki

Department of Dermatology, Faculty of Medicine, University of Tokyo and
1 Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan

Objective. To determine the prevalence of the anti-U5 small nuclear ribonucleoprotein (snRNP) antibody in patients with systemic sclerosis.

Methods. Sera from 281 patients with systemic sclerosis, including 10 patients with overlapping polymyositis, were assayed using RNA immunoprecipitation and protein immunoprecipitation.

Results. Only one serum sample showed precipitation of U5 snRNA with scarce precipitation of U2, U1, U4 and U6 snRNAs. In addition, the serum precipitated a 200 kDa protein. The serum was from a 35-yr-old Japanese male patient with overlapping systemic sclerosis and polymyositis accompanied by large-cell lung carcinoma. The clinical appearance was similar to that of a case reported previously.

Conclusion. The presence of the anti-U5 snRNP antibody in serum may be specific for scleroderma–polymyositis overlap syndrome.

KEY WORDS: Scleroderma–polymyositis overlap, Anti-U5 snRNP antibody, Lung carcinoma, Immunoprecipitation.

Correspondence to: H. Ihn.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
P. Szodoray, P. Alex, M. B. Frank, M. Turner, S. Turner, N. Knowlton, C. Cadwell, I. Dozmorov, Y. Tang, P. C. Wilson, et al.
A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis
Rheumatology, December 1, 2006; 45(12): 1466 - 1476.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.